Use of rhu-GM-CSF in pulmonary tuberculosis patients: results of a randomized clinical trial
It has been postulated that deficient or incomplete clinical and/or microbiological response to tuberculosis treatment is associated with cell-mediated immunological dysfunction involving monocytes and macrophages. A phase 2 safety trial was conducted by treating patients with either recombinant hum...
Main Authors: | , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2003-01-01
|
Series: | Brazilian Journal of Infectious Diseases |
Subjects: | |
Online Access: | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702003000400004 |
id |
doaj-7fc88b6298ef430fbd138ef3360de59f |
---|---|
record_format |
Article |
spelling |
doaj-7fc88b6298ef430fbd138ef3360de59f2020-11-25T03:06:26ZengElsevierBrazilian Journal of Infectious Diseases1413-86701678-43912003-01-0174245252Use of rhu-GM-CSF in pulmonary tuberculosis patients: results of a randomized clinical trialPedral-Sampaio Diana BrasilNetto Eduardo MartinsBrites CarlosBandeira Antonio CarlosGuerra ConceiçãoBarberin Maria GorethBadaró RobertoIt has been postulated that deficient or incomplete clinical and/or microbiological response to tuberculosis treatment is associated with cell-mediated immunological dysfunction involving monocytes and macrophages. A phase 2 safety trial was conducted by treating patients with either recombinant human granulocyte-macrophage colony-stimulating factor (rhu-GM-CSF) or a placebo, both in combination with anti-tuberculosis chemotherapy. Thirty-one patients with documented pulmonary tuberculosis were treated with rifampin/isoniazid for six months, plus pyrazinamide for the first two months. At the beginning of treatment, rhu-GM-CSF (125µg/M²) was randomly assigned to 16 patients and injected subcutaneously twice weekly for four weeks; the other 15 patients received a placebo. The patients were accompanied in the hospital for two weeks, then monthly on an out patient basis, for 12 months. Clinical outcomes were similar in both groups, with no difference in acid-fast bacilli (AFB) clearance in sputum at the end of the fourth week of treatment. Nevertheless, a trend to faster conversion to negative was observed in the rhu-GM-CSF group until the eighth week of treatment (p=0.07), after which all patients converted to AFB negative. Adverse events in the rhu-GM-CSF group were local skin inflammation and an increase in the leukocyte count after each injection, returning to normal 72 hours after rhu-GM-CSF injection. Three patients developed SGOP and SGPT > 2.5 times the normal values. All patients included in the GM-CSF group were culture negative at six months, except one who had primary TB resistance. None of the patients had to discontinue the treatment in either group. We conclude that rhu-GM-CSF adjuvant immunotherapy could be safely explored in a phase 3 trial with patients who have active tuberculosis.http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702003000400004TuberculosisGM-CSFtreatment |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Pedral-Sampaio Diana Brasil Netto Eduardo Martins Brites Carlos Bandeira Antonio Carlos Guerra Conceição Barberin Maria Goreth Badaró Roberto |
spellingShingle |
Pedral-Sampaio Diana Brasil Netto Eduardo Martins Brites Carlos Bandeira Antonio Carlos Guerra Conceição Barberin Maria Goreth Badaró Roberto Use of rhu-GM-CSF in pulmonary tuberculosis patients: results of a randomized clinical trial Brazilian Journal of Infectious Diseases Tuberculosis GM-CSF treatment |
author_facet |
Pedral-Sampaio Diana Brasil Netto Eduardo Martins Brites Carlos Bandeira Antonio Carlos Guerra Conceição Barberin Maria Goreth Badaró Roberto |
author_sort |
Pedral-Sampaio Diana Brasil |
title |
Use of rhu-GM-CSF in pulmonary tuberculosis patients: results of a randomized clinical trial |
title_short |
Use of rhu-GM-CSF in pulmonary tuberculosis patients: results of a randomized clinical trial |
title_full |
Use of rhu-GM-CSF in pulmonary tuberculosis patients: results of a randomized clinical trial |
title_fullStr |
Use of rhu-GM-CSF in pulmonary tuberculosis patients: results of a randomized clinical trial |
title_full_unstemmed |
Use of rhu-GM-CSF in pulmonary tuberculosis patients: results of a randomized clinical trial |
title_sort |
use of rhu-gm-csf in pulmonary tuberculosis patients: results of a randomized clinical trial |
publisher |
Elsevier |
series |
Brazilian Journal of Infectious Diseases |
issn |
1413-8670 1678-4391 |
publishDate |
2003-01-01 |
description |
It has been postulated that deficient or incomplete clinical and/or microbiological response to tuberculosis treatment is associated with cell-mediated immunological dysfunction involving monocytes and macrophages. A phase 2 safety trial was conducted by treating patients with either recombinant human granulocyte-macrophage colony-stimulating factor (rhu-GM-CSF) or a placebo, both in combination with anti-tuberculosis chemotherapy. Thirty-one patients with documented pulmonary tuberculosis were treated with rifampin/isoniazid for six months, plus pyrazinamide for the first two months. At the beginning of treatment, rhu-GM-CSF (125µg/M²) was randomly assigned to 16 patients and injected subcutaneously twice weekly for four weeks; the other 15 patients received a placebo. The patients were accompanied in the hospital for two weeks, then monthly on an out patient basis, for 12 months. Clinical outcomes were similar in both groups, with no difference in acid-fast bacilli (AFB) clearance in sputum at the end of the fourth week of treatment. Nevertheless, a trend to faster conversion to negative was observed in the rhu-GM-CSF group until the eighth week of treatment (p=0.07), after which all patients converted to AFB negative. Adverse events in the rhu-GM-CSF group were local skin inflammation and an increase in the leukocyte count after each injection, returning to normal 72 hours after rhu-GM-CSF injection. Three patients developed SGOP and SGPT > 2.5 times the normal values. All patients included in the GM-CSF group were culture negative at six months, except one who had primary TB resistance. None of the patients had to discontinue the treatment in either group. We conclude that rhu-GM-CSF adjuvant immunotherapy could be safely explored in a phase 3 trial with patients who have active tuberculosis. |
topic |
Tuberculosis GM-CSF treatment |
url |
http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702003000400004 |
work_keys_str_mv |
AT pedralsampaiodianabrasil useofrhugmcsfinpulmonarytuberculosispatientsresultsofarandomizedclinicaltrial AT nettoeduardomartins useofrhugmcsfinpulmonarytuberculosispatientsresultsofarandomizedclinicaltrial AT britescarlos useofrhugmcsfinpulmonarytuberculosispatientsresultsofarandomizedclinicaltrial AT bandeiraantoniocarlos useofrhugmcsfinpulmonarytuberculosispatientsresultsofarandomizedclinicaltrial AT guerraconceicao useofrhugmcsfinpulmonarytuberculosispatientsresultsofarandomizedclinicaltrial AT barberinmariagoreth useofrhugmcsfinpulmonarytuberculosispatientsresultsofarandomizedclinicaltrial AT badaroroberto useofrhugmcsfinpulmonarytuberculosispatientsresultsofarandomizedclinicaltrial |
_version_ |
1724674102142173184 |